Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

The Effect of Tofacitinib on Live Vaccine Responses

Richard Quinn  |  February 26, 2016

New research indicates that vaccination for the herpes zoster virus in patients with rheumatoid arthritis starting tofacitinib appears to be both safe and useful. Rheumatologists may want to check the patient’s pre-existing immunity status prior to administering the vaccine…

Cholesterol Levels in Patients with RA Starting Methotrexate

Arthritis & Rheumatology  |  February 25, 2016

Although research regarding the increased cardiovascular (CV) morbidity and mortality in rheumatoid arthritis (RA) has burgeoned in recent years, the need remains for a better understanding of the effects of widely used DMARDs on CV risk and risk factors in RA patients. These authors set out to evaluate the long-term changes in cholesterol levels in patients with early RA. Decreases in RA disease activity over long-term follow-up were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies…

2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention

Mary Beth Nierengarten  |  February 17, 2016

SAN FRANCISCO—Evolving research into the pathogenesis of rheumatoid arthritis (RA) is increasingly showing that rather than a single causative dysfunctional pathway leading to disease, multiple pathways are involved, the study of which can shed additional light on what is occurring in a person’s body prior to developing symptoms of disease. Saying it another way, no…

Case Study in Dermatology: Tender Papules on Elbows, Hands in RA

Drew Kurtzman, MD, & Timothy McCalmont, MD, with Ruth Ann Vleugels, MD, MPH, & Joseph F. Merola, MD, MMSc  |  February 17, 2016

The Case A 41-year-old woman was referred to the dermatology clinic for a three-month history of tender lesions on her elbows and around the joints of her hands. Her medical history was notable for seropositive, non-erosive rheumatoid arthritis (RA), which was being treated with 5 mg pred­nisone daily, 10 mg methotrexate weekly by mouth, 200…

2015 ACR/ARHP Annual Meeting: Research Offers Clues to Environmental Triggers of RA

Susan Bernstein  |  February 16, 2016

SAN FRANCISCO—Research is revealing more clues about the environmental factors that likely play a role in triggering rheumatoid arthritis (RA) in patients who are susceptible—or that may even protect them from autoimmunity. Large-scale, lengthy population studies conducted at institutions worldwide provide in-depth data from which to identify potential triggers and protective factors for RA, from…

Tofacitinib Decreases Inflammation in Early RA

Michele B. Kaufman, PharmD, BCGP  |  February 12, 2016

A recent study used MRI to show that tofacitinib reduces inflammation and inhibition of the progression of structural damage in adults with early RA…

Textile Workers at Higher Risk for Rheumatoid Arthritis

Lisa Rapaport  |  February 12, 2016

(Reuters Health)—Breathing textile dust on the job is linked to an almost tripled risk of developing rheumatoid arthritis (RA), a Malaysian study suggests. While smoking is a known risk factor for RA, the findings add to evidence suggesting that environmental factors could trigger RA in some people, the researchers note in their report in Annals…

Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Laura Newman  |  February 2, 2016

NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University…

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Laura Newman  |  January 21, 2016

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…

Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Louise Grech, BPharm (Hons), MPhil, MRPharmS, Victor Ferrito, BSc, MSc, PhD, CSci, Liberato Camilleri, BEd, MSc, PhD, Anthony Serracino Inglott, BPharm, PharmD, MRPharmS, & Lilian M. Azzopardi, BPharm (Hons), MPhil, PhD, MRPharmS  |  January 19, 2016

Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…

  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences